Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report issued on Sunday. The firm set a “sell” rating on the stock.

Other equities research analysts have also issued reports about the stock. Maxim Group lowered their price target on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th. Roth Mkm reissued a “buy” rating and issued a $40.00 price objective on shares of Moleculin Biotech in a research report on Friday, April 12th.

Moleculin Biotech Stock Down 7.5 %

Shares of NASDAQ:MBRX opened at $4.30 on Friday. Moleculin Biotech has a 12 month low of $4.28 and a 12 month high of $15.75. The company’s fifty day simple moving average is $6.93 and its 200 day simple moving average is $8.10. The firm has a market cap of $9.59 million, a price-to-earnings ratio of -0.32 and a beta of 1.96.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC purchased a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned 9.60% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.